Logo
x

Search

Subscribe Now

Prevention

Nutraceuticals Under Evaluation for COVID-19 Prevention and Treatment

Nutraceuticals Under Evaluation for COVID-19 Prevention and Treatment

  • June 24, 2021
AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

AstraZeneca's AZD7442 Fails to Meet its Primary Endpoint in P-III STORM CHASER Study for the Prevention of Symptomatic COVID-19

  • June 15, 2021
Takeda Reports EMA's Acceptance of TAK-003 for the Prevention of Dengue

Takeda Reports EMA's Acceptance of TAK-003 for the Prevention of Dengue

  • March 26, 2021
Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COVID-19

Elli Lilly Reports Results of Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) in P-III BLAZE-1 Study for the Prevention of COV...

  • March 11, 2021
Roche's Xofluza (baloxavir marboxil) Receives the US FDA's Approval for Post-Exposure Prevention of Influenza

Roche's Xofluza (baloxavir marboxil) Receives the US FDA's Approval for Post-Exposure Prevention of Influenza

  • November 24, 2020
PolyPid's D-PLEX₁₀₀ Receives the US FDA's Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Colorectal Surgery

PolyPid's D-PLEX₁₀₀ Receives the US FDA's Breakthrough Therapy Designation for the Prevention of Surgical Site Infections in Color...

  • November 24, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.